Fig. 5From: Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viabilityCD13 protein expression levels (ng/ml) in cell lysate of HEPG2 cells or HEPG2 transfected with hepatitis B virus (HBV/HEPG2) after 48 h incubation with different concentrations of Taz or 0.05% DMSO; (***): P < 0.001Back to article page